Vanda Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $47,651 | $50,474 | $47,462 | $45,271 |
Gross Profit | 45,100 | 45,989 | 42,004 | 41,811 |
EBITDA | -9,033 | -8,178 | -7,011 | -5,936 |
EBIT | -11,000 | -10,146 | -9,235 | -7,094 |
Net Income | -5,324 | -4,518 | -4,146 | -2,400 |
Net Change In Cash | 47,651 | 50,474 | 47,462 | 45,271 |
Free Cash Flow | -14,742 | -7,036 | 7,562 | -3,985 |
Cash | 100,497 | 102,953 | 125,158 | 135,821 |
Basic Shares | 58,261 | 58,220 | 57,760 | 57,532 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $192,640 | $254,382 | $268,682 | $248,168 |
Gross Profit | 192,640 | 230,100 | 243,053 | 224,804 |
EBITDA | -13,952 | 9,062 | 45,006 | 30,103 |
EBIT | -13,952 | 6,329 | 42,165 | 27,239 |
Net Income | 2,509 | 6,275 | 33,152 | 23,337 |
Net Change In Cash | 192,640 | 254,382 | 268,682 | 248,168 |
Cost of Revenue | 82,643 | -8,932 | 15,910 | |
Free Cash Flow | 12,418 | 31,305 | 63,662 | 49,980 |
Cash | 135,821 | 135,029 | 52,071 | 61,031 |
Basic Shares | 57,557 | 56,983 | 56,921 | 55,190 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.09 |
2024-06-30 | -$0.08 |
2024-03-31 | -$0.07 |
2023-12-31 | -$0.04 |
